Blueprint Medicines Corp (BPMC)
105.51
-0.85
(-0.80%)
USD |
NASDAQ |
May 31, 16:00
105.64
+0.13
(+0.12%)
After-Hours: 20:00
Blueprint Medicines Research and Development Expense (TTM): 406.04M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 406.04M |
| December 31, 2023 | 429.92M |
| September 30, 2023 | 450.23M |
| June 30, 2023 | 467.96M |
| March 31, 2023 | 486.36M |
| December 31, 2022 | 477.42M |
| September 30, 2022 | 716.46M |
| June 30, 2022 | 672.89M |
| March 31, 2022 | 624.46M |
| December 31, 2021 | 601.03M |
| September 30, 2021 | 321.56M |
| June 30, 2021 | 311.37M |
| March 31, 2021 | 322.42M |
| December 31, 2020 | 326.86M |
| September 30, 2020 | 338.10M |
| June 30, 2020 | 345.32M |
| March 31, 2020 | 341.35M |
| December 31, 2019 | 331.45M |
| September 30, 2019 | 313.34M |
| Date | Value |
|---|---|
| June 30, 2019 | 296.44M |
| March 31, 2019 | 267.92M |
| December 31, 2018 | 243.62M |
| September 30, 2018 | 216.72M |
| June 30, 2018 | 191.46M |
| March 31, 2018 | 166.15M |
| December 31, 2017 | 144.69M |
| September 30, 2017 | 125.13M |
| June 30, 2017 | 103.98M |
| March 31, 2017 | 91.98M |
| December 31, 2016 | 81.13M |
| September 30, 2016 | 73.49M |
| June 30, 2016 | 67.02M |
| March 31, 2016 | 56.99M |
| December 31, 2015 | 48.59M |
| September 30, 2015 | 43.49M |
| June 30, 2015 | 40.18M |
| March 31, 2015 | 35.70M |
| December 31, 2014 | 31.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
296.44M
Minimum
Jun 2019
716.46M
Maximum
Sep 2022
429.05M
Average
375.68M
Median
Research and Development Expense (TTM) Benchmarks
| Ligand Pharmaceuticals Inc | 23.84M |
| Apellis Pharmaceuticals Inc | 329.06M |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Biomarin Pharmaceutical Inc | 779.91M |
| Cytokinetics Inc | -- |